Inventiva Files its 2024 Half-Year Report
Inventiva, a prominent clinical-stage biopharmaceutical company, is making significant strides in the healthcare sector. Focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis, commonly known as MASH/NASH, the company recently announced its filing of the 2024 Half-Year Report for the period ending June 30, 2024.
Key Highlights from the 2024 Half-Year Report
The half-year report was filed with the French financial markets authority, AMF. The financial statements, prepared under the governance of Inventiva's Board of Directors, confirm a going concern basis. This decision was reached amidst a climate of uncertainties that could impact the company's future viability.
Financial Overview
Inventiva's report indicates that the financial information remained unqualified by statutory auditors during the stated period. However, the audit report from the preceding year highlighted concerns regarding the company's ability to maintain operations as a going concern, illustrating the careful scrutiny under which the company is operating.
Insights into Company Operations
Inventiva is moving forward with considerable focus on its lead product candidate, lanifibranor, which is currently undergoing a pivotal Phase III clinical trial named NATiV3. This trial targets adult patients suffering from MASH/NASH, a severe liver condition that is increasingly recognized in the clinical landscape.
Innovative Product Pipeline
In addition to lanifibranor, Inventiva has developed a promising pipeline featuring odiparcil, aimed at treating MPS VI in adults. While the company has chosen to prioritize its resources towards lanifibranor, odiparcil remains in a watchful state, with the company evaluating future development pathways.
Expertise and Infrastructure
The backbone of Inventiva's innovative spirit lies in its dedicated team of approximately 90 professionals. This team is deeply entrenched in various fields, including biology, medicinal chemistry, and clinical development. Their capabilities are further augmented by an extensive library of pharmacologically relevant compounds.
Company Listings and Contact Information
As a notable player in biopharmaceutical investments, Inventiva is publicly traded on Euronext Paris under the ticker IVA and on Nasdaq under the same ticker symbol. It also has an alternate listing, IVEVF. For those interested in learning more or requiring engagement, contact details include:
Contact Inventiva:
Pascaline Clerc, PhD
EVP, Strategy and Corporate Affairs
media@inventivapharma.com
+1 202 499 8937
Media Relations:
Brunswick Group
Tristan Roquet Montegon / Aude Lepreux / Julia Cailleteau
inventiva@brunswickgroup.com
+33 1 53 96 83 83
Investor Relations:
Westwicke, an ICR Company
Patricia L. Bank
patti.bank@westwicke.com
+1 415 513-1284
Frequently Asked Questions
What is the focus of Inventiva's research?
Inventiva primarily develops oral small molecule therapies for treating MASH/NASH and other significant unmet medical needs.
What is the significance of the 2024 Half-Year Report?
This report outlines the company's financial health, ongoing trials, and strategic focus for the upcoming periods.
What clinical stage is lanifibranor currently in?
Lanifibranor is undergoing a pivotal Phase III clinical trial known as NATiV3.
How does Inventiva handle its drug pipeline?
Inventiva manages a diverse pipeline while prioritizing candidate development based on unmet medical needs.
Where can I find more information about Inventiva?
More details can be accessed through Inventiva's official website or by contacting their media and investor relations departments.
